Trial Profile
Inappropriate dosing and patterns in patients with atrial fibrillation treated with rivaroxaban and apixaban
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2017
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Apixaban
- Indications Stroke
- Focus Therapeutic Use
- 28 Nov 2017 New trial record
- 15 Nov 2017 Results presented at the 90th Annual Scientific Sessions of the American Heart Association